利拉鲁肽对肥胖相关性高血压患者miRNA-132表达的影响及临床疗效

Effect of Liraglutide on miRNA-132 Expression in Obesity-Related Hypertensive Patients and Its Clinical Efficacy

目的:探讨miRNA-132在肥胖相关性高血压患者中的表达及临床意义,分析利拉鲁肽治疗肥胖相关性高血压对miRNA-132表达的影响及临床疗效。方法:选取2021年1~10月医院收治的60岁及以上被确诊为肥胖相关性高血压患者50例为肥胖相关性高血压组和健康人群50例为健康人群组。采用实时荧光定量PCR方法检测血清miRNA-132水平,采用受试者工作特征(ROC)曲线分析miRNA-132对肥胖相关性高血压的诊断价值。再将50例肥胖相关性高血压患者随机分为对照组与观察组,各25例。对照组给予氨氯地平片治疗,观察组在对照组治疗基础上给予利拉鲁肽注射液治疗。比较肥胖相关性高血压组和健康人群组miRNA-132表达水平,对照组与观察组miRNA-132表达水平、体质量指数(BMI)、血压、生化指标及临床疗效。结果:肥胖相关性高血压组血清miRNA-132的表达水平显著低于健康人群组(P<0.05);ROC曲线分析显示,miRNA-132诊断肥胖相关性高血压的曲线下面积为0.945,灵敏度为94.0%,特异度为78.0%。治疗6个月后,观察组miRNA-132表达水平与对照组相比,明显升高(P<0.05);观察组BMI、血压、甘油三酯、低密度脂蛋白胆固醇、空腹血糖、糖化血红蛋白及同型半胱氨酸浓度改善均优于对照组(P<0.05);观察组治疗总有效率为96.00%,高于对照组的68.00%(P<0.05);观察组药物不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。结论:miRNA-132在肥胖相关性高血压患者血清中表达降低,对其具有诊断价值;利拉鲁肽可显著增加肥胖相关性高血压患者miRNA-132的表达,具有减肥、降压及保护心血管效应。

Objective: To investigate the expression and clinical significance of miRNA-132 in patients with obesity-related hypertension, and to analyze the effect of liraglutide on the expression of miRNA-132 and its clinical efficacy in the treatment of obesity-related hypertension. Methods: A total of 50 patients aged 60 years and above diagnosed with obesity-related hypertension admitted to the hospital from January to October 2021 were selected as the obesity-related hypertension group and 50 healthy people as the healthy group. Serum miRNA-132 levels were detected by real-time PCR,and the diagnostic value of miRNA-132 in obesity-related hypertension was analyzed by receiver operating characteristic(ROC) curve. Then 50 patients with obesity-related hypertension were randomly divided into control group and observation group, 25 cases in each group. The control group was treated with amlodipine tablets, and the observation group was treated with liraglutide injection on the basis of the control group. The expression levels of miRNA-132 in obesity-related hypertension group and healthy group were compared. miRNA-132 expression level, body mass index(BMI), blood pressure, biochemical indexes and clinical efficacy in the control group and the observation group. Results: The expression level of serum miRNA-132 in obesity-related hypertension group was significantly lower than that in healthy group(P<0.05).ROC curve analysis showed that the area under the curve of miRNA-132 in the diagnosis of obesity-related hypertension was 0.945, the sensitivity was 94.00%, and the specificity was 78.00%. After 6 months of treatment, the expression level of miRNA-132 in the observation group was significantly higher than that in the control group(P<0.05). The improvement of BMI, blood pressure, triglyceride, low density lipoprotein cholesterol, fasting blood glucose, glycosylated hemoglobin and homocysteine in the observation group were better than those in the control group(P<0.05). The total effective rate of the observation group was 96.00%, which was higher than 68.00% of the control group(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the observation group and the control group(P >0.05).Conclusion: The expression of miRNA-132 in serum of patients with obesity-related hypertension is decreased, which has diagnostic value for it. Liraglutide can significantly increase the expression of miRNA-132 in obesity-related hypertensive patients, and has weight loss, reduce blood pressure and cardiovascular protection effects.